| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ART.11157 |
| P698 | PubMed publication ID | 12847691 |
| P2093 | author name string | Shu-Jen Chen | |
| John Varga | |||
| Yasuji Mori | |||
| P2860 | cites work | Deficient Smad7 expression: a putative molecular defect in scleroderma | Q34021184 |
| P433 | issue | 7 | |
| P304 | page(s) | 1964-1978 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts | |
| P478 | volume | 48 |
| Q90467962 | A novel miRNA-4484 is up-regulated on microarray and associated with increased MMP-21 expression in serum of systemic sclerosis patients |
| Q33637862 | A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses |
| Q54962214 | Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib). |
| Q35863725 | Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis |
| Q42525511 | Akt blockade downregulates collagen and upregulates MMP1 in human dermal fibroblasts |
| Q35689019 | Antifibrotic therapy in scleroderma: extracellular or intracellular targeting of activated fibroblasts? |
| Q34358613 | Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts |
| Q37903252 | Autoimmune mechanisms of scleroderma and a role of oxidative stress |
| Q37621644 | Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. |
| Q39987550 | Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1. |
| Q35070899 | Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors |
| Q35170133 | Constitutive Smad signaling and Smad-dependent collagen gene expression in mouse embryonic fibroblasts lacking peroxisome proliferator-activated receptor-gamma |
| Q38327280 | Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts |
| Q38543692 | Cytokines in the immunopathology of systemic sclerosis |
| Q37866690 | Deconstructing fibrosis research: do pro-fibrotic signals point the way for chronic dermal wound regeneration? |
| Q42600316 | Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis |
| Q41037995 | Differentiation, apoptosis, and GM-CSF receptor expression of human gingival fibroblasts on a titanium surface treated by a dual acid-etched procedure |
| Q34555185 | Dihydrosphingosine 1-phosphate has a potent antifibrotic effect in scleroderma fibroblasts via normalization of phosphatase and tensin homolog levels |
| Q84164263 | Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis |
| Q34447925 | Fibrillin assemblies: extracellular determinants of tissue formation and fibrosis |
| Q37791685 | Fibrosis and immune dysregulation in systemic sclerosis |
| Q34687049 | Ha-Ras stabilization mediates pro-fibrotic signals in dermal fibroblasts. |
| Q42354635 | Helen Ollendorff Curth: A dermatologist's lasting legacy. |
| Q42354702 | Helen Ollendorff-Curth: A dermatologist's lasting legacy |
| Q35745090 | Hematopoietic stem cell-derived cancer-associated fibroblasts are novel contributors to the pro-tumorigenic microenvironment |
| Q34257607 | Histone deacetylase: a potential therapeutic target for fibrotic disorders |
| Q64096057 | Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients |
| Q37386864 | Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. |
| Q37509808 | Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity |
| Q89766137 | Kelch-like protein 42 is a profibrotic ubiquitin E3 ligase involved in systemic sclerosis |
| Q28288338 | Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis |
| Q35094477 | Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease |
| Q36577428 | Mechanisms and consequences of fibrosis in systemic sclerosis |
| Q26781257 | MicroRNAs Regulating Signaling Pathways: Potential Biomarkers in Systemic Sclerosis |
| Q36354729 | Molecular aspects of regulation of collagen gene expression in fibrosis. |
| Q33745028 | PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis |
| Q37326935 | Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator |
| Q28238030 | Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes |
| Q26863751 | Recent developments in myofibroblast biology: paradigms for connective tissue remodeling |
| Q37688362 | SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis |
| Q36506934 | Scar wars: is TGFbeta the phantom menace in scleroderma? |
| Q36067741 | Scleroderma, fibroblasts, signaling, and excessive extracellular matrix |
| Q36891532 | Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma |
| Q35649427 | Systemic sclerosis: a prototypic multisystem fibrotic disorder |
| Q58659630 | T cell repertoire in patients with stable scleroderma |
| Q35102837 | Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma |
| Q35899944 | The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor β Signaling |
| Q37852901 | The lens as a model for fibrotic disease |
| Q52657100 | The non-neuronal cyclin-dependent kinase 5 is a fibrotic mediator potentially implicated in systemic sclerosis and a novel therapeutic target. |
| Q35689005 | The pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosis |
| Q58783029 | The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis |
| Q34452923 | Therapeutic potential of trichostatin A to control inflammatory and fibrogenic disorders of the ocular surface |
| Q41347489 | Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment |
| Q34232534 | Transforming growth factor-beta and fibrosis |
| Q25255541 | Tweaking microtubules to treat scleroderma |
| Q37638268 | Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities |
| Q36717858 | Valproic acid suppresses collagen by selective regulation of Smads in conjunctival fibrosis |
| Q64046177 | [Systemic sclerosis: pathophysiology of a multifaceted disease] |
Search more.